A number of other research firms also recently commented on GSK. Jefferies Financial Group set a GBX 1,475 ($17.44) price objective on GSK in a report on Thursday, September 8th. Credit Suisse Group set a GBX 1,430 ($16.91) price objective on GSK in a research report on Thursday, November 3rd. Deutsche Bank Aktiengesellschaft reissued a hold rating and issued a GBX 1,500 ($17.74) price target on shares of GSK in a report on Wednesday, November 16th. UBS Group set a GBX 1,300 ($15.37) price target on GSK in a report on Friday, November 11th. Finally, Barclays set a GBX 1,450 ($17.15) price target on GSK in a report on Wednesday, November 9th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of GBX 1,622 ($19.18).
GSK Price Performance
Shares of LON GSK opened at GBX 1,380 ($16.32) on Tuesday. The stock’s 50-day moving average is GBX 1,363.14 and its two-hundred day moving average is GBX 1,540.46. The company has a debt-to-equity ratio of 253.74, a current ratio of 0.97 and a quick ratio of 0.73. GSK has a 1-year low of GBX 1,280.92 ($15.15) and a 1-year high of GBX 1,824.40 ($21.57). The company has a market cap of £56.13 billion and a price-to-earnings ratio of 1,266.06.
GSK Cuts Dividend
Insider Buying and Selling
In other news, insider Jonathan Symonds acquired 3,220 shares of the stock in a transaction that occurred on Thursday, September 29th. The stock was purchased at an average cost of GBX 1,324 ($15.66) per share, with a total value of £42,632.80 ($50,411.26). Over the last 90 days, insiders have acquired 3,237 shares of company stock worth $4,286,706.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.